XML 28 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities    
Net loss $ (31,350) $ (30,726)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities    
Depreciation and amortization 2,903 2,793
Amortization of convertible notes debt discount 4,389 262
Stock‑based compensation expense 3,709 170
Change in fair value of warrant liability 1,252 104
Change in contingent consideration 818 4,114
Change in fair value of put option   2,000
Accrued interest on notes payable and convertible notes payable 1,226 799
Amortization of debt issuance costs 144 144
Provision for doubtful accounts 296 246
Loss on disposals of assets 48 13
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in acquisitions:    
Accounts receivable (10,308) (3,646)
Other current assets (6,588) 1
Other long-term assets and liabilities (1,808) 16
Accounts payable and other accrued liabilities 11,654 1,193
Deferred revenue 2,249 791
Net cash and cash equivalents and restricted cash used in operating activities (21,366) (21,726)
Cash flows from investing activities    
Purchase of property and equipment (1,945) (1,310)
Patent costs and intangible asset acquisition, net (232) (106)
Payments to acquire Oncimmune assets (750) (456)
Net cash and cash equivalents and restricted cash used in investing activities (2,927) (1,872)
Cash flows from financing activities    
Proceeds from initial public offering 72,000  
Proceeds from exercise of common stock options 1,340 47
Proceeds from issuance of series H preferred stock   10,000
Proceeds from issuances of convertible notes payable 12,955 13,044
Proceeds from paycheck protection program note payable 3,085  
Equity financing costs (8,243) (3)
Other (6) (116)
Net cash and cash equivalents and restricted cash provided by financing activities 81,131 22,972
Net increase (decrease) in cash and cash equivalents and restricted cash 56,838 (626)
Cash, cash equivalents, and restricted cash ‑ beginning of period 5,468 6,094
Cash, cash equivalents, and restricted cash ‑ end of period 62,306 5,468
Supplemental cash flow information    
Conversion of preferred stock into common stock 193,959  
Conversion of convertible notes and accrued interest into common stock 26,616  
Reclassification of put option liability to additional paid-in capital 6,650  
Value of put option recorded at issuance of convertible debt payable 3,389 1,261
Cash paid for interest 1,844 1,800
Reclassification of warrant liability to additional paid-in capital $ 1,624  
Accrued business combination payments   $ 750